title: Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies.
abstract: Despite evidence showing the importance of continuous medication in preventing relapse in patients with schizophrenia and the harmful consequences that relapse can have, clinical efforts often focus on hospital-based treatment or treatment of acute exacerbations of schizophrenia rather than on ensuring appropriate and effective relapse prevention. Inadequate compliance with antipsychotic treatment further deters from the goal of long-term management of schizophrenia; however, appropriate use of injectable, long-acting antipsychotic medications--especially atypical antipsychotics--has the potential to increase compliance and thus improve the long-term prognosis of patients with schizophrenia. A long-acting formulation of the atypical antipsychotic risperidone has undergone large-scale clinical testing, during which it showed significant improvement on measures of disease severity while maintaining an acceptable side effect profile.
authors.affiliation: Albert Einstein College of Medicine, Bronx, NY, USA.
authors.forename: John M
authors.initials: JM
authors.lastname: Kane
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D016032:Randomized Controlled Trials as Topic; D018967:Risperidone / Q000008:administration & dosage* / Q000009:adverse effects; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D055502:Secondary Prevention; D016312:Treatment Refusal / Q000523:psychology
chemical_list: D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations; D018967:Risperidone